AngioDynamics, Inc. provided sales guidance for the Fiscal Year 2024. For the year, the company expects net sales to be in the range of $270 million to $275 million which reflects the recent divestiture of the PICC and Midline businesses and discontinuance of the RadioFrequency ablation and Syntrax businesses, which accounted for approximately $50 million of the prior revenue guidance of $320 to $325 million. The Company expects gross margin to be approximately 52.0% to 54.0%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.36 USD | +3.08% | +7.98% | -18.88% |
May. 06 | AngioDynamics, Inc. Announces Results from the Acute Pulmonary Embolism Extraction Trial with the Alphavac System (APEX-AV) | CI |
Apr. 08 | North American Morning Briefing : Inflation Data, -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.88% | 247M | |
-4.98% | 181B | |
+2.84% | 112B | |
-2.68% | 67.92B | |
+4.53% | 50.1B | |
+8.00% | 44.27B | |
+9.59% | 40.41B | |
+25.30% | 31.95B | |
-0.17% | 25.82B | |
+21.27% | 25.29B |
- Stock Market
- Equities
- ANGO Stock
- News AngioDynamics, Inc.
- AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2024